Real-world effectiveness of MET inhibitors versus immunotherapy ± chemotherapy in 1L for patients with MET exon 14 skipping mutations in non-small cell lung cancer.

作者：Pranoti Pradhan, Rohini George, Kamal S. Saini, Sharanya J., Rūta Veinalde, Maria Ignacia Berraondo, Paulo Nunes Filho, Carolina Dutra, Ullas Batra, Federica Pecci, Biagio Ricciuti, Jennifer Rider, Luca Cantini · 发表于：Journal of Clinical Oncology · 年份：2026 · DOI：10.1200/jco.2026.44.16_suppl.8645 · 研究领域：Lung Cancer Treatments and Mutations、Fibroblast Growth Factor Research、Melanoma and MAPK Pathways

8645 Background: Metastatic non-small cell lung cancer (mNSCLC) remains a leading cause of cancer-related deaths, with MET exon 14 skipping mutations (METex14) identified as a key oncogenic driver in 1%–4% of cases. MET tyrosine kinase inhibitors (TKI) such as capmatinib and tepotinib have demonstrated efficacy in clinical trials, leading to FDA approval in any treatment line. This study aims to compare first-line (1L) survival outcomes with MET TKI versus immune checkpoint inhibitors ± chemotherapy (IO ± Chemo). Methods: Patient characteristics and survival outcomes were retrospectively analyzed for METex14 mNSCLC patients who received 1L therapy with either (1) MET TKI (tepotinib and capmatinib) or (2) IO ± Chemo. Patients were excluded if they had EGFR alterations. Data were sourced from ConcertAI's Patient360 and RWD360, datasets sourced from oncology EHR in the US. Results: Among a total of 344 patients, 174 (50.6%) were > 80 years of age, 94 (87.9%) had non-squamous mNSCLC, 176 (51.2%) were female, and 71 (20.6%) had ECOG PS ≥2. As 1L, 202 received MET TKI, 61 received IO + Chemo, and 81 received IO only. Baseline clinicopathologic features were balanced except for a slightly higher proportion of patients with TPS PD-L1 ≥50 in the IO ± Chemo group ( p < 0.05). At a median follow up of 40.7 months (mo), in the overall group median progression-free survival (mPFS) was 6.6 mo (95% CI: 5.8–8.8) and median overall survival (mOS) was 15.5 mo (95% CI: 14.4–18.3). MET TKI...